Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: Implications for antineoplastic combination therapies

Neoplasia (United States)

Volumn 14, Issue 9, 2012, Pages 846-854

  Bonezzi, Katiuscia ^a   Belotti, Dorina ^a   North, Brian J ^b   Ghilardi, Carmen ^a   Borsotti, Patrizia ^a   Resovi, Andrea ^a   Ubezio, Paolo ^a   Riva, Antonella ^c   Giavazzi, Raffaella ^a   Verdin, Eric ^b   Taraboletti, Giulia ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INDENA S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IDN 5390; PACLITAXEL; SIRTUIN 2; SIRTUIN INHIBITOR; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR FKHRL1; TRICHOSTATIN A; TUBULIN; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CHEMOTAXIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MICROTUBULE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; WESTERN BLOTTING;

EID: 84866526603     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12728     Document Type: Article

References (4)

1. North BJ, Marshall BL, Borra MT, Denu JM, and Verdin E (2003). The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 11, 437-444.
2. Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, Scanziani E, Eccles SA, Bani MR, and Giavazzi R (2006). The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin Cancer Res 12, 1839-1849.
3. Taraboletti G, Micheletti G, Rieppi M, Poli M, Turatto M, Rossi C, Borsotti P, Roccabianca P, Scanziani E, Nicoletti MI, et al. (2002). Antiangiogenic and antitumor activity of IDN5390, a new taxane derivative. Clin Cancer Res 8, 1182-1188.
4. Belotti D, Rieppi M, Nicoletti MI, Casazza AM, Fojo T, Taraboletti G, and Giavazzi R (1996). Paclitaxel (Taxol®) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. Clin Cancer Res 2, 1725-1730.